What is beyond the Nivolumab Monotherapy approval for advanced Hepatocellular Carcinoma?
Journal Title: Open Access Journal of Oncology and Medicine - Year 2018, Vol 1, Issue 2
Abstract
With an estimated 500,000 new cases per year, hepatocellular carcinoma (HCC) represents the third leading cause of cancer death worldwide. The incidence is rising in the west, largely due to an increasing incidence of hepatitis C virus infection [1]. The majority of HCC patients are diagnosed with disease too advanced for curative treatment. Only liver resection and liver transplantation are considered curative, with poor efficiency of other modalities such as radiofrequency ablation (RFA) and transarterial chemoembolization (TACE), although this may provide a modest prolongation in survival; however, the relapse in the majority of these patients is inevitable [2]. An array of translational research and pilot clinical trials have revealed that adoptive immunotherapy's are safe by patients with HCC, but they lack efficacy [3]. Now, we are in the new era of immunotherapy's such as immune checkpoint inhibitors and CAR-T strategies, which would bring benefit to the HCC patients. On September 22, 2017, the Food and Drug Administration granted accelerated approval to nivolumab (OPDIVO, Bristol- Myers Squibb Co.) for the treatment of HCC in patients who have been previously treated with sorafenib. The approval was based on a 154-patient subgroup of CHECKMATE-040 (NCT 01658878), a multicenter, open-label trial conducted in patients with HCC and Child-Pugh.
Authors and Affiliations
Luis Mendoza
Keywords
Related Articles
- EP ID EP583053
- DOI 10.32474/OAJOM.2018.01.000109
- Views 74
- Downloads 0
Promising Role of Fractional Calculus in Biomedicine and Biophysics
The study of complex systems and investigation of their structural and dynamical properties have attracted considerable interests among scientists in general and physicists, biologists and medical researchers in particul...
Immunotherapy in Some Types of Tumors
Immunotherapy exerts its antitumor action by stimulating the response immune response of patients to cancer, unlike classic treatments, which directly attack the tumor. Previously immunotherapy was limited to patients in...
Spinal Meningioma: Pathophysiology, Diagnosis and Management
Tumors have several types that can build up in or near the spine. There are many types of spinal tumors. They can appoint the spinal cord, nerve roots or the vertebrae (bones of the spine) and pelvis. Spinal tumors have...
The Potential Role of Thioctic Acid in the Attenuation of Doxorubicin Induced-Cardiotoxicity
During 1950s in Italy a soil sample was isolated and found new strains of Streptomyces peucetius bacteria from which a new antibiotic was extracted with potent effect against murine tumors, this antibiotic named daunorub...
Checkpoint Inhibitors in Squamous Non-Small Cell Lung Cancer (NSCLC)
Checkpoint inhibitors have demonstrated efficacy in squamous NSCLC with tolerable toxicity profile. They are used as a monotherapy, in combination with chemotherapy or following chemo-radiotherapy as a first line, second...